TSE:4568Pharmaceuticals
Daiichi Sankyo Waiv Alliance Ties AI Pathology To ADC Valuation Story
Daiichi Sankyo (TSE:4568) has formed a partnership with Waiv to use AI-driven digital pathology for biomarker discovery in its antibody-drug conjugate program.
The collaboration centers on applying computational pathology to identify biomarkers that may help predict which patients respond best to specific ADC candidates.
The agreement is aimed at improving the efficiency and clinical precision of Daiichi Sankyo's oncology research and development efforts.
Daiichi Sankyo, a global...